Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma

Multiple myeloma has a continued need for more effective and durable therapies. B cell maturation antigen (BCMA), a plasma cell surface antigen and member of the tumor necrosis factor (TNF) receptor superfamily, is an attractive target for immunotherapy of multiple myeloma due to its high prevalence...

Descripción completa

Detalles Bibliográficos
Autores principales: Bu, De-Xiu, Singh, Reshma, Choi, Eugene E., Ruella, Marco, Nunez-Cruz, Selene, Mansfield, Keith G., Bennett, Paul, Barton, Nathanial, Wu, Qilong, Zhang, Jiquan, Wang, Yongqiang, Wei, Lai, Cogan, Shawn, Ezell, Tucker, Joshi, Shree, Latimer, Kellie J., Granda, Brian, Tschantz, William R., Young, Regina M., Huet, Heather A., Richardson, Celeste J., Milone, Michael C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995247/
https://www.ncbi.nlm.nih.gov/pubmed/29899820
http://dx.doi.org/10.18632/oncotarget.25359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995247/
https://www.ncbi.nlm.nih.gov/pubmed/29899820
http://dx.doi.org/10.18632/oncotarget.25359

Ejemplares similares